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ABSTRACT  
 
Animal models have shown that tau seeding and propagation are strain- and neural network-
specific. The study of preclinical cases is valuable to gain insights into early pathological 
features of corticobasal degeneration and its progression. 
Three preclinical corticobasal degeneration cases and six age-matched end-stage corticobasal 
degeneration cases were included in this study. Tau immunohistochemistry performed in 
twenty brain regions and quantitative assessment of regional tau load using image analysis 
were performed. Semi-quantitative grading of tau-positive cellular lesions and neuronal loss 
in the frontal, parietal and temporal cortices, striatum, substantia nigra and subthalamic 
nucleus were assessed.  
All preclinical cases were clinically asymptomatic but had widespread tau lesions in the 
typically affected regions in corticobasal degeneration and the pathognomonic astrocytic 
plaques were the most prominent lesion type in the anterior frontal and striatal regions. Mean 
total tau load (sum of all regional tau load) of end-stage corticobasal degeneration controls 
were nine times greater than that of the preclinical cases (P = 0.04) and less tau load was 
found in all regions of the preclinical cases. An anterior-to-posterior tau load ratio in the 
frontal cortex in preclinical cases was 12-fold greater than in end-stage corticobasal 
degeneration cases. Relatively greater tau burden in the anterior frontal cortex, striatum and 
subthalamic nucleus suggest the striatal afferent connection to the dorsolateral prefrontal 
cortex and basal ganglia circuitry are the earliest neural network connections affected by 
corticobasal degeneration-related tau pathology. Differential distribution to selective cortical 
regions in these preclinical cases implies phenotypic presentation may be predetermined at a 
very early stage of the disease process. Neuronal loss of the substantia nigra was either absent 
or very mild in the preclinical cases and was moderate to severe in end-stage corticobasal 
degeneration cases (P < 0.05).  
Our findings suggest that a threshold of pathological burden in the ‘right’ anatomical regions 
needs to be reached before the onset of clinical symptoms. The early prominent astrocytic 
plaques in relation to trivial neuronal lesions leads one to speculate that corticobasal 
degeneration may begin as an astrogliopathy at a very early disease stage but neuronal lesion 
gradually takes over as the predominant lesion type in advanced disease.  
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INTRODUCTION 
 
Corticobasal degeneration (CBD) is a progressive neurodegenerative tauopathy characterised 
by the accumulation of hyperphosphorylated 4-repeat tau in the neurons and glia in both 
cortical and subcortical regions(Dickson et al., 2002). Astrocytic plaques are pathognomonic 
for CBD and are numerous in affected cerebral cortical areas and the striatum. Neuropil 
threads are usually numerous and, along with neurofibrillary tangles, pretangles and 
oligodendroglial coiled bodies, are widespread but are generally greater in the cortex and 
basal ganglia than in the brainstem and cerebellum. αB-crystallin-immunoreactive ballooned 
neurons are common and support the diagnosis of CBD (Fig. 1). They are observed in the 
cortical regions, more frequently in the superior frontal gyrus. In affected cortical areas, 
spongiosis is usually most evident in layers two and three and astrogliosis is prominent at the 
grey-white matter junction with myelin loss and microgliosis in the cerebral white matter. 
Loss of pigmented cells and gliosis in the substantia nigra are consistent findings. 
 
Similar to progressive supranuclear palsy (PSP)(Ling et al., 2013), which is also a 4-repeat 
tauopathy, the distribution of neuronal loss and severity of tau pathology in CBD closely 
correlate with its heterogeneous clinical presentations(Kouri et al., 2011). Corticobasal 
syndrome (CBS) is the classic presentation with asymmetrical focal cortical signs including 
limb apraxia, dystonia and akinetic-rigidity (CBD-CBS)(Rebeiz et al., 1967, 1968). 
Clinicopathological studies have shown that other phenotypes such as Richardson syndrome 
(CBD-RS; i.e. a PSP-like syndrome) and frontotemporal dementia (FTD) including behavior 
variant FTD (CBD-bvFTD) or primary progressive aphasia (CBD-PPA) may be more 
common than CBS, as a clinical manifestation of CBD pathology(Ling et al., 2010). Clinical 
criteria have been proposed to capture the different clinical phenotypes caused by underlying 
CBD pathology(Armstrong et al., 2013). MRI studies showed that cortical atrophy in CBD-
CBS was most marked in the posterior half of the frontal lobe with the superior frontal gyrus 
being often more affected than the middle and inferior frontal gyri(Whitwell et al., 2010). In 
such cases, the pre- and postcentral regions are also affected to varying degrees, but the 
temporal and occipital lobes are usually spared. In CBD-bvFTD and CBD-PPA, atrophy is 
more severe in the frontal and temporal lobes(Whitwell and Josephs, 2012).  
 
Hierarchical staging schemes depicting stereotypic spatiotemporal progression of neuronal 
vulnerability as the disease progresses have been proposed for conditions with tau pathology 
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such as Alzheimer’s disease(Braak et al., 2006), argyrophilic grain disease(Saito et al., 2004), 
Pick’s disease(Irwin et al., 2016) and chronic traumatic encephalopathy(McKee et al., 2013) 
as well as for Parkinson’s disease(Braak et al., 2003), a synucleinopathy, 
bvFTD(Brettschneider et al., 2014) and amyotrophic lateral sclerosis(Brettschneider et al., 
2013) with phosphorylated 43-kDa TAR DNA-binding protein (TDP-43) pathology. Animal 
models and functional magnetic resonance imaging studies have suggested that the 
progression of tau pathology in conditions such as Alzheimer’s disease, CBD and PSP are 
strain- and neural network-specific(Clavaguera et al., 2009; Clavaguera et al., 2013; 
Niethammer et al., 2014; Piattella et al., 2015; Ahmed et al., 2016). In recent years, the 
concepts of tau seeding, cell-to-cell and region-to-region ‘spread’ of tau pathology, analogous 
to the prion-like conformational templating mechanism and supported by experimental data 
and pathological observations, have been proposed as the mechanism responsible for the 
progression in these neurodegenerative conditions(Lewis and Dickson, 2016). The study of 
preclinical cases provides a unique resource to detect early pathological changes of the 
neurodegenerative condition. Similar concepts have been proposed in incidental Lewy body 
disease representing either preclinical Parkinson’s disease(Dickson et al., 2008) or dementia 
with Lewy bodies(Frigerio et al., 2011) and in preclinical Alzheimer’s disease(Braak et al., 
2011). In CBD, the regions affected early by tau pathology and its subsequent spatiotemporal 
progression are not known. This study quantitatively analysed the CBD pathological changes 
in 3 preclinical cases and compared them with end-stage CBD cases with an aim to determine 
the early pathological features of CBD.  
 
 
MATERIALS AND METHODS 
 
Case material 
As part of a large-scale study on CBD, we collected 130 CBD cases from 12 UK, European 
and USA centres. Of these, three cases were identified to have preclinical CBD pathology. 
These cases had the pathological hallmarks of CBD but were clinically asymptomatic. Six 
age-matched end-stage CBD cases were selected as controls, three of which had the clinical 
phenotype of CBS (CBD-CBS) and three clinically presented with Richardson syndrome 
(CBD-RS). All six end-stage CBD cases had clinically advanced disease following 
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progressive deterioration and died of end-stage disease; their post-mortem findings fulfilled 
the pathological diagnostic criteria for CBD(Dickson et al., 2002). End-stage CBD cases with 
minimal concurrent Alzheimer-type and vascular pathologies were selected. Histological 
examination and diagnostic confirmation were established in all cases by a neuropathologist 
(TR). This Queen Square Brain Bank study was approved by a London Multi-Centre 
Research Ethics Committee and tissue is stored for research under a license from the Human 
Tissue Authority. Clinical information was extracted from all available medical records by a 
neurologist (HL). 
 
Neuropathological methods 
For Cases 2 and 3, tissue slides were requested from Taub Institute for Research on 
Alzheimer’s disease and the Aging Brain, Columbia University Medical Center, New York, 
USA and the Institute of Neurology, Medical University of Vienna, Austria, respectively. For 
Case 1 (from Queen Square Brain Bank) and all six end-stage CBD cases, the brains were 
divided in the mid-sagittal plane. One half, chosen randomly, was frozen, and the other half 
was immersed and fixed in 10% buffered formalin for 3 weeks before neuropathological 
examination. Tissue blocks were taken using the Queen Square Brain Bank protocol. Eight-
µm-thick histological sections were stained using routine histological (haematoxylin and 
eosin, H&E) and silver staining (Gallyas)(Braak et al., 2011) techniques. 
Immunohistochemistry with antibodies to the following proteins: tau (AT8 clone; Thermo 
scientific MN1020; 1:600), 3-repeat tau (Gift from Dr Rohan de Silva; 1:150,) and 4-repeat 
tau (Gift from Dr Rohan de Silva; 1:750), AT100 (Thermo Scientific MN1060; 1:200), αB-
crystallin (Leica Biosystems NCL-ABCrys-512, clone G2JF; 1:300), amyloid-β (Aβ; 
Biosource international, Camarillo, CA, Mouse Dako, clone 6F/3D; 1:100), transactive 
response DNA-binding protein 43 kDa (TDP-43; monoclonal; clone 2E2-D3; 1:2000), p62 
(BD Transduction Labs, Oxford, UK; 1:200) and α-synuclein (Novocastra, Milton Keynes, 
UK; 1:50) was performed using a standard avidin-biotin method. The following additional 
pathologies were systematically assessed: p62-positive neuronal cytoplasmic inclusions seen 
in cases with C9orf72 mutation, cerebral amyloid angiopathy, argyrophilic grain 
disease(Saito et al., 2004) and TDP-43 proteinopathy. For determining the level of 
Alzheimer’s disease neuropathological change, ABC score were established according to the 
National Institute on Aging-Alzheimer’s Association (NIA-AA) Guidelines(Hyman et al., 
2012).  
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Quantitative analysis of tau load 
Twenty brain regions which are known to be affected in CBD and whose involvement is 
predicted to contribute to the clinical features were selected: the anterior frontal cortex 
(Brodmann area 9 or prefrontal cortex) grey matter and white matter, posterior frontal cortex 
(Brodmann area 4 or primary motor cortex) grey and white matter, middle temporal gyrus 
(Brodmann area 21) grey and white matter, superior parietal lobule (Brodmann area 7) grey 
and white matter, hippocampal formation (CA1-4, granular cell layer of the dentate gyrus, 
subiculum), amygdala, caudate, putamen, globus pallidus, subthalamic nucleus, midbrain 
tectum and tegmentum, pontine tegmentum and base, cerebellar dentate nucleus and white 
matter. The posterior frontal cortex and the subthalamic nucleus were not available in Case 2.  
 
Histological AT8-stained slides were digitized on a LEICA SCN400F scanner (LEICA 
Milton Keynes, UK) with a x20 objective. Slides were viewed and managed on LEICA 
Slidepath (LEICA Milton Keynes, UK). Brain regions of interest were manually selected and 
digitally outlined (HL and KD) using Definiens Developer 2.3 (Definiens, Munich, 
Germany). Threshold was adjusted to capture the two-dimensional area of all AT8-stained 
lesions (brown) and the same threshold setting was used for all cases. For each selected 
region, the ‘areal fraction’, defined by the ratio of the total area occupied by the tau-
immunoreactive lesions and the entire area of interest, was computed by Definiens Developer 
2.3 (Definiens, Munich, Germany). ‘Regional’ tau load for each brain region was expressed 
as percentage (areal fraction x 100%)(Gundersen et al., 1988). ‘Total’ tau load was the sum 
of tau load in all 20 regions. ‘Cortical’ tau load was the sum of tau load of grey and white 
matter of the anterior frontal, posterior frontal, temporal and parietal regions. ‘Basal ganglia’ 
tau load was the sum of tau load of the caudate, putamen, globus pallidus and subthalamic 
nucleus. 
 
Quantitative analysis of cellular lesion types 
Tau-positive cellular lesions including neuronal lesions (neurofibrillary tangles and 
pretangles), astrocytic plaques and coiled bodies were manually counted (by HL), while 
neuropil threads were graded semi-quantitatively using a four-tier scale (0-3 with grade 0 = 
absent to grade 3 = severe) at x20 objective in 5 random fields (3 random fields in the 
substantia nigra, subthalamic nucleus and cerebellar dentate nucleus due to their relatively 
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small regional areas) in selected brain regions. A mean score for each lesion type was 
generated for each brain region. Semi-quantitative analysis of different cellular lesion types 
using a four-tier scale was performed in the hippocampal formation.  
 
Neuronal loss in the substantia nigra 
Neuronal loss in the substantia nigra was determined using a four-tier semi-quantitative 
grading system by a neuropathologist (TR): 0-3 with grade 0 = no neuronal loss to grade 3 = 
most severe neuronal loss. The substantia nigra was divided for the grading assessment into 5 
subregions: medial, dorsomedial, dorsolateral, ventrolateral and lateral. 
 
MAPT gene sequencing  
DNA was extracted from the frozen brain tissue of the three preclinical CBD cases.  Exons 
10-13 of the MAPT gene were screened through Sanger sequencing for known pathological 
mutations. MAPT haplotypes were determined through the H1/H2-tagging SNP 
rs1052553(Pittman et al., 2005).   
 
Statistical analysis 
The SPSS 24.0 statistical package (IBM Corporation, New York, USA) was used. Log 
transformation was performed to normalize data where indicated including regional, total, 
cortical and basal ganglia tau load. Student’s t-test and ANOVA were used to compare mean 
tau load (Log10), and continuous demographic data. Pearson χ
2
 test was used to compare the 
neuronal-to-astrocytic lesion ratios between the two CBD groups. Multiple regression 
analysis was performed to study which of the cellular lesion types best correlate with tau load 
in the cortical regions. P value of 0.05 was used. Corrections for multiple comparisons of 
mean regional tau load were performed using a P value of 0.0031 (16 regions of interest). 
However, due to the small sample size of the preclinical cases, results without adjustment for 
multiple comparisons are also reported and discussed.  
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RESULTS 
 
Overview 
The 3 preclinical CBD cases (Cases 1-3) were clinically asymptomatic for any progressive 
neurodegenerative disorder and incidental findings of histological hallmarks of CBD 
including astrocytic plaques (Fig. 1) and a combination of neuronal and glial tau pathologies 
were identified at post-mortem. Six end-stage CBD cases were selected as age-matched 
controls and were made up of two different clinical phenotypes, CBD-CBS (N = 3) and 
CBD-RS (N = 3).  
The mean age at death of the preclinical CBD group was 76.0 years (SD = 13.0), whereas the 
mean age at death of the six end-stage CBD cases and our large end-stage CBD cohort 
collected from 12 international centres for an ongoing pathological staging study was 70.2 
years (SD = 5.2, vs. preclinical CBD cases: P = 0.35) and 70.6 years (N = 109, SD = 7.9, 
range = 48 to 88 years, vs. preclinical CBD cases: P = 0.25), respectively. The mean disease 
duration from symptom onset to death of the CBD-CBS and CBD-RS groups was 6.7 years 
and 4.3 years, respectively (P = 0.07). The demographic features of these 9 cases were 
summarized in Table 1.  
 
Case summary  
Case 1 (London, UK) 
This case was included in our published CBD case series(Ling et al., 2010). This man had 
motor tics since the age of 8 and developed vocal tics in his late teens. He had lifelong 
anxiety disorder and an obsessive-compulsive personality trait. Four generations of his family 
had had a history of motor tics. He was followed up with the neuropsychiatrists at the 
National Hospital for Neurology and Neurosurgery, Queen Square, London, during which he 
joined the Queen Square Brain Bank donor programme. He died of metastatic carcinoma of 
the prostate at the age of 63.  
 
Tau immunohistochemistry revealed moderate number of astrocytic plaques in the anterior 
frontal region. Occasional neurofibrillary tangles, pretangles and neuropil threads were seen 
mainly in the anterior frontal, entorhinal and transentorhinal cortices. Sparse neuropil threads 
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were observed in the posterior frontal, parietal and temporal regions. No ballooned neurons 
were found on αB-crystallin immunohistochemistry (Fig. 1). In the striatum, there were 
frequent astrocytic plaques, moderate threads, few neurofibrillary tangles and occasional 
oligodendroglial coiled bodes. In the putamen, tau pathologies were more prominent in the 
medial than lateral region. Moderate neuropil threads and few neurofibrillary tangles were 
seen in the amygdala, substantia nigra and subthalamic nucleus. A few neuropil threads were 
observed in the locus coeruleus. Scattered neurofibrillary tangles and threads were observed 
in the midbrain tectum and tegmentum, pontine tegmentum and cerebellar dentate nucleus. 
Astrocytic plaques, neurofibrillary tangles, pretangles and threads were immunoreactive for 
4-repeat tau but not 3-repeat tau. Mild pigment incontinence was seen in the substantia nigra. 
The volume of the subthalamic nucleus, locus coeruleus and cerebellar dentate nucleus was 
well-preserved. 
 
Case 2 (New York, USA) 
This man was a participant in the Washington Heights and Inwood and Columbia Aging 
Project and was clinically referred to as a ‘healthy control’ brain donor at the New York 
Brain Bank. His last scheduled neurological assessment which took place a few months prior 
to his death at age 89 concluded ‘normal cognition’ and neurological examination was 
normal.  
 
Tau immunohistochemistry revealed moderate number of astrocytic plaques in the frontal 
cortex and striatum and, to a lesser extent, in the temporal region and rarely in the parietal 
region. There were also scattered neurofibrillary tangles and neuropil threads in these cortical 
regions as well as in the hippocampal formation, amygdala, striatum, globus pallidus, 
midbrain tectum, tegmentum, substantia nigra, locus coeruleus and pontine tegmentum. 
Rarely, a couple of scattered coiled bodies were observed in the cortical regions. These tau-
lesions were immunoreactive for 4-repeat tau but not for 3-repeat tau. No ballooned neurons 
were found on αB-crystallin immunohistochemistry. There was no evidence of cell loss in the 
cortices, substantia nigra, locus coeruleus, subthalamic nucleus and dentate nucleus. 
 
Case 3 (Vienna, Austria) 
The clinical and pathological features of this case were described in a case report(Milenkovic 
and Kovacs, 2013). In brief, this woman had polycystic kidney disease and chronic renal 
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insufficiency. Shortly following renal transplantation, she developed acute graft rejection and 
was treated with immunosuppressants, but eventually succumbed to septic shock and multiple 
organ failure at the age of 76. 
 
Mild neuronal loss and gliosis were observed in the parietal, temporal and entorhinal cortices 
and substantia nigra. Moderate gliosis was observed in the caudate. Occasional ballooned 
neurons immunoreactive for αB-crystallin were found only in the anterior cingulate cortex. 
Mild to moderate tau pathologies including astrocytic plaques, neurofibrillary tangles, 
pretangles, threads and occasional coiled bodies were seen in the frontal cortex, striatum, 
substantia nigra, hippocampus, amygdala and, to a lesser extent, parietal, temporal and 
entorhinal cortices, globus pallidus and subthalamic nucleus. Few neuropil threads were 
detected in the locus coeruleus. Argyrophilic grains (Stage II) immunoreactive for 4-repeat 
tau and p62 antibodies were observed in the hippocampal formation(Saito et al., 2004). Mild 
pigment incontinence was seen in the substantia nigra. There was no evidence of neuronal 
loss in the frontal cortex, subthalamic nucleus and locus coeruleus.  
 
Quantitative analysis of tau load 
Regional tau load 
The mean regional tau load of the preclinical CBD group was less than that of the end-stage 
CBD group with statistically significant difference identified in 16 selected regions (P < 
0.05). For the remaining 4 selected regions, there was borderline significance in the anterior 
frontal grey matter, parietal white matter and putamen, and no statistical significance in the 
amygdala (P = 0.15)(Fig. 2 & Fig. 3). After adjusting for multiple comparisons, significant 
difference in mean regional tau load between the preclinical and end-stage groups was 
identified in the following regions: posterior frontal grey and white matter, temporal grey 
matter, caudate nucleus, midbrain tectum, and pontine tegmentum. The regional tau load data 
of selected brain regions of the preclinical CBD cases are illustrated in Supplementary Fig. 1. 
 
Frontal tau load distribution 
Of all the cortical regions, the most abundant tau load in the preclinical CBD group was 
identified in the frontal cortex. Within the frontal cortex, the predominant tau load was 
observed in the anterior frontal region and tau lesions in the posterior frontal region were 
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very sparse (Fig. 4). This finding was in contrast with the severe tau load in the posterior 
frontal region usually found in end-stage CBD-CBS cases. The mean anterior-to-posterior 
frontal tau load ratio (including both grey and white matter) of the preclinical CBD group 
was 16.04 and that of the end-stage CBD group was 1.36. Thus, the anterior-posterior 
gradient of tau distribution in the frontal region of the preclinical CBD group was almost 12 
folds greater than that of the end-stage CBD group. 
 
Total, cortical and basal ganglia tau load 
The total (P = 0.04) and basal ganglia (P = 0.001) tau load of the preclinical CBD group were 
significantly less than those of the end-stage CBD group. Although cortical tau load of the 
preclinical CBD group was numerically less than that of the end-stage CBD group, there was 
no significant difference statistically (P = 0.19)(Supplementary Fig. 2). 
 
Cellular lesion types 
Overview 
The distribution and severity of different tau lesion types based upon quantitative analysis are 
illustrated in Fig. 5. In the preclinical cases, an anterior-posterior gradient in the distribution 
of all cellular lesion types could be observed in the frontal cortex with these lesions being 
mainly restricted to the anterior frontal region rather than the posterior frontal region. 
 
Neuronal lesions and neuropil threads 
In end-stage CBD, neuronal lesions (e.g. neurofibrillary tangles and pretangles) were most 
prominent in the frontal and parietal cortices, amygdala, caudate, subthalamic nucleus and 
pontine tegmentum; while in preclinical CBD, neuronal lesions were mainly found, to a 
lesser extent than in the end-stage cases, in the anterior frontal and parietal regions, amygdala 
and the basal ganglia (Fig. 5). In end-stage CBD, severe neuropil thread pathology was 
observed in the frontal region, basal ganglia, midbrain tectum, whereas in the preclinical 
cases, mild thread pathology was found in the frontal cortex, amygdala and basal ganglia and 
was almost absent in other regions with scattered neuropil threads occasionally observed in 
the temporal and parietal cortices and cerebellar white matter. 
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Astrocytic plaques 
In end-stage CBD cases, moderate numbers of astrocytic plaques were observed in the 
frontal, parietal and temporal cortices, amygdala and striatum. In the preclinical cases, 
astrocytic plaques were most abundant in the striatum, and were observed in mild to 
moderate density in the anterior frontal, parietal and temporal cortices. astrocytic plaques 
were uncommon in the brainstem and cerebellum in both groups. 
 
Coiled bodies 
In our end-stage CBD cases, oligodendroglial coiled bodies were in general less common 
than other lesion types and were occasionally observed the cortical white matter, lentiform 
nucleus and brainstem, whereas in preclinical CBD, very occasional coiled bodies were 
observed in the anterior frontal region and lentiform nucleus.  
 
Tau lesion types in the cortical regions 
In the end-stage CBD cases, neuronal lesions in the cortical regions were at least 4 times 
more abundant than astrocytic plaques; while the proportion of these two lesion types was 
similar in the preclinical CBD cases (Supplementary Fig. 3). The average ratio of neuronal 
lesions to astrocytic plaques in the four cortical regions (anterior and posterior frontal, 
parietal and temporal cortical grey matter) was 0.91 in the preclinical CBD group and 4.20 in 
the end-stage CBD group (P < 0.001; χ
2
 test). 
Multiple regression analysis was performed to investigate which of the cellular lesion type 
best correlates with regional tau load in cortical grey matter (Supplementary Fig. 4). In the 
preclinical CBD cases, there was a significant correlation between neuronal lesions and 
regional tau load (P = 0.002, R
2
 = 0.98), while in the end-stage CBD cases, neuropil threads 
(P < 0.001) and neuronal lesions (P = 0.056, borderline significance) significantly correlated 
with regional tau load (R
2
 = 0.87). Other lesion types such as astrocytic plaques and coiled 
bodies did not correlate with the regional tau load in either CBD group.  
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Tau lesion types in the hippocampal formation 
The distribution and severity of neuronal and thread pathologies in the hippocampal 
formation are illustrated in Supplementary Fig. 5. Tau lesions in the hippocampal subregions 
were very mild in preclinical Cases 1 and 2. In preclinical Case 3 and most of the end-stage 
CBD cases, severe neuronal and thread pathologies were observed in CA1 and the granular 
cell layer even in cases with no or minimal Alzheimer’s disease-related changes and absence 
of argyrophilic grains (e.g. Cases 4-6). In preclinical CBD cases, mild astrocytic plaques 
were observed in CA1, subiculum (Cases 1 and 2), and entorhinal cortex (Cases 1 and 3). 
Astrocytic plaques were observed in the entorhinal cortex of three of the six end-stage CBD 
cases, ranging from mild (Cases 4 and 8) to severe (Case 9).  
 
AT100 immunohistochemistry 
For both the preclinical and end-stage CBD cases, the tau-positive lesions (neurofibrillary 
tangles, pretangles, neuropil threads, astrocytic plaques and coiled bodies) were also 
immunoreactive with antibody AT100 (Fig. 1). This finding indicated that disease-associated 
tau in all lesion types observed in the preclinical cases was phosphorylated at serine 212 and 
threonine 214 and was in advanced stage of the aggregation process and formed filaments i.e. 
tau was in the same conformation as the tau lesions in end-stage cases (Clavaguera et al., 
2009). 
 
Cell loss in substantia nigra 
Semi-quantitative assessment of cell loss using a four-tier rating scale in five substantia nigra 
subregions showed that the cell loss was either absent or very mild in the preclinical cases, 
while in the end-stage cases, the nigral cell loss ranged from moderate to severe (medial, 
dorsomedial and ventromedial subregions: P = 0.03, χ
2
 test), with the ventrolateral subregion 
being most severely and consistently affected in all six end-stage cases (P = 0.01; χ
2
 test); one 
exception was in the dorsolateral subregion (P = 0.06, borderline significance; χ
2
 test) where 
cell loss was found to be mild in a CBD-CBS case (Case 4)(Fig. 6).  
 
Secondary pathologies 
Secondary pathologies in preclinical and end-stage cases are summarized in Table 1. 
Argyrophilic grains were observed in one preclinical case (Case 3, Vienna). Mild cortical Aβ 
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pathology was observed in another preclinical case (Thal phase 1, Case 2, New York, age of 
death: 89 years). TDP-43, α-synuclein, vascular and cerebral amyloid angiopathy pathologies 
were not identified in any of the preclinical cases.  
 
MAPT gene sequencing  
Sanger sequencing of MAPT gene for any known pathological mutations in exons 10-13 were 
negative in all three preclinical CBD cases. Preclinical Cases 1 and 3 had H1/H1 and Case 2 
had H1/H2 MAPT haplotypes.  
 
 
DISCUSSION 
 
We described the histological features of three clinically asymptomatic cases with CBD-tau 
lesions in both neurons and glia. These lesions were immunoreactive with the AT8, AT100 
and anti-4-repeat tau antibodies but not with the antibody to 3-repeat tau. Astrocytic plaques 
with Gallyas-positive and tau-imunoreactive annular clusters of short processes were seen, 
most prominently in the striatum followed by the anterior frontal and parietal regions. The 
severity of neuronal lesions and neuropil threads followed a rostro-caudal descending 
gradient from the forebrain to the hindbrain structures but the overall tau burden in the 
preclinical cases was significantly less than the end-stage CBD cases. Cortical neuronal loss, 
spongiosis, ballooned neurons, thinning of the corpus callosum, nigral cell loss, all of which 
are considered to be characteristic features of end-stage CBD, were consistently observed in 
all six of our end-stage CBD cases, but were either absent or minimal in the three preclinical 
cases. We interpreted these histological findings as early CBD pathology and the lack of 
clinical symptoms was due to subthreshold pathology.  
 
The distribution and severity of neuronal loss and tau pathology are closely associated with 
the clinical syndrome in CBD as in other neurodegenerative conditions (Boxer et al., 2006; 
Whitwell et al., 2010; Ling et al., 2013). The lack of significant neuronal loss in the cortex, 
substantia nigra and less total tau load in our preclinical CBD cases when compared with 
end-stage CBD cases suggest that a threshold of pathological burden in the ‘right’ anatomical 
regions needs to be reached for the onset of clinical symptoms. Despite the relatively smaller 
number of tau lesions, the tau pathology in preclinical cases is widespread and shows a 
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topographical distribution that is overall similar to that observed in end-stage cases. As the 
total tau load of Case 3 was four- and five-fold greater than Cases 1 and 2, it is reasonable to 
assume that Cases 1 and 2 are at an earlier stage of the pathological process than Case 3.  
 
In Case 1, cortical pathology was very mild and was mainly observed in the anterior frontal 
region, followed by the posterior frontal region, relatively dense tau pathology was also 
found in the striatum and subthalamic nucleus. In Case 2, tau pathology was similarly 
distributed in the frontal and temporal grey and white matter. In Case 3, predominant cortical 
tau pathology was observed in the anterior frontal and parietal regions as well as in the 
hippocampus, amygdala and caudate with moderate gliosis in the caudate. In a quantitative 
study comparing the tau distribution of CBD-CBS and CBD-RS, Kouri et al showed that 
CBD-CBS cases had significantly greater tau burden in the primary motor and somatosensory 
cortices of both grey matter and white matter and putamen than in CBD-RS cases and that tau 
burden in the anterior frontal cortex (superior frontal gyrus) was the same in both CBD 
phenotypes. Phenotypic presentation of CBD is probably predetermined at a very early stage 
as seen in our preclinical cases. If these individuals had lived for longer and the disease 
process were allowed to evolve, Case 2 may have developed an FTD syndrome based on the 
early predominant tau distribution in the frontal and temporal regions, while Cases 1 and 3 
may have had the classic CBS phenotype in view of the early frontal and striatal involvement. 
Similar to most brain bank protocols, only one brain hemisphere of each case was processed 
for histological studies and was available for this study. In view of the predilection of tau 
accumulation in different cortical regions early in the disease process, it is possible that 
interhemispheric asymmetry of pathology is already evident in these preclinical cases(Oide et 
al., 2002; Boxer et al., 2006; Hassan et al., 2010), but remains at a subthreshold level 
bilaterally.  
 
In Cases 1 and 3, tau pathology was more prominent in the anterior frontal region (prefrontal 
cortex) than in the posterior frontal (precentral gyrus involving primary motor cortex). 
Unfortunately, the posterior frontal region in Case 2 was not available for analysis. A 12-fold 
greater anterior-to-posterior frontal tau load ratio was found in these preclinical cases when 
compared with the end-stage group. This anterior-posterior gradient suggests the initial site of 
tau accumulation in the frontal cortex is likely to be the anterior frontal region, while the 
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posterior frontal area is involved at a later stage. Symptom onset of CBS probably coincides 
with the threshold of pathological burden in the primary motor cortex being reached. 
 
The distribution of cellular lesion types differed between the preclinical and end-stage cases. 
In the anterior frontal cortex, the mean astrocytic plaque count was 2.5 (range: 0 to 10;  
averaging over 5 random fields at x20 objective) in Cases 1 and 2 with sparse threads and 
absence of neuronal lesions, while the mean neuronal and astrocytic plaque counts in the 
anterior frontal cortex of Case 3 were 6 and 4.6, respectively. In end-stage cases, neuronal 
lesions in the anterior frontal cortex were three times greater than astrocytic plaques (13.6 to 
4.1). Likewise, in the striatum, a region with one of the highest mean tau load in both CBD 
groups, the mean neuronal and astrocytic plaque counts in Cases 1 and 2 were 2.2 and 13.0, 
and in Case 3, they were 5.4 and 5. In the end-stage CBD cases, neuronal lesions in the 
striatum were twice as many as astrocytic plaques (7.9: to 3.2). These findings indicate that 
astrocytic plaques were the predominant lesion type in the anterior frontal cortex and striatum 
of Cases 1 and 2, which were thought to be at an earlier disease stage than Case 3. It is 
possible that astrocytic plaques are the arliest tau lesion type that occurs in regions affected 
early by the CBD pathological process, leading us to speculate that CBD may begin as an 
astrogliopathy. Based upon the findings in Case 3 and end-stage cases, it appears that as the 
pathology progresses, neuronal lesions markedly increase in number and eventually overtake 
astrocytic plaques as the predominant lesion type. Notably, in some end-stage cases, very 
dense thread pathology observed in the cerebral cortex and some subcortical grey nuclei may 
mask a proportion of the astrocytic plaques. Josephs et al studied the correlation between 
disease duration and lesion types in PSP and noted that cases with the most severe neuronal 
tau pathology had the longest disease duration (Josephs et al., 2006), indicating that neuronal 
tau pathology, rather than astrogliopathy, is the most abundant cellular lesion type in end-
stage PSP, another 4-repeat  tauopathy. Multiple regression analysis has identified a 
correlation between neuronal lesions and regional tau load in the preclinical group. This 
finding may be explained by the larger tau-immmunoreactive area attributed by neuronal 
lesions in Case 3. 
 
In end-stage CBD, there is a variable degree of neuronal loss and gliosis in the substantia 
nigra (Dickson et al., 2002). Neuronal loss in the ventrolateral nigral cell groups correlates 
with extrapyramidal features in parkinsonism(Fearnley and Lees, 1991); whereas neuronal 
loss in the medial nigra correlates more with cognitive and frontal behavioural deficits(Rinne 
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et al., 1989) and were more severely affected in CBD-RS than CBD-CBS(Kouri et al., 2011). 
This finding was also confirmed by the present study. Our end-stage CBD-RS cases had more 
severe neuronal loss in the medial (P = 0.014) and dorsomedial (P = 0.014) tiers when 
compared with CBD-CBS cases and severe neuronal loss (grade 3 all) was observed in the 
ventrolateral tier in both phenotypes. Pirker et al reported two post-mortem confirmed CBD 
cases with mildly reduced tracer uptake in dopamine transporter SPECT scan in early disease 
stage (1.5 years after symptom onset), and subsequently, the tracer uptake markedly declined 
later in the disease course (4.5 and 5 years after symptom onset)(Pirker et al., 2015). Our 
group previously reported a pathologically confirmed CBD case with normal dopamine 
transporter SPECT tracer uptake more than 4 years into the illness(O'Sullivan et al., 2008). 
These findings suggest that nigrostriatal degeneration may be a late pathological feature of 
CBD. In our preclinical cases, tau pathology in the substantia nigra was mild and the cell 
population in all nigral subregions was either preserved or showed very mild cell loss (range: 
grade 0 to 0.5 in all subregions of all three preclinical cases), indicating nigral cell loss takes 
place later in the disease course. 
 
Severe neuronal loss and gliosis in the subthalamic nucleus is a prerequisite for the 
pathological diagnosis of PSP(Hauw et al., 1994), but it is not a consistent feature in end-
stage CBD. Only three of the six end-stage CBD cases showed mild neuronal loss with 
gliosis in the subthalamic nucleus, while the volume of the remaining three cases was 
preserved. In the preclinical cases, the subthalamic nucleus has one of the highest tau burden 
and tau lesions (mild to moderate neurofibrillary tangles, pretangles and neuropil threads), 
with preserved volume. Neuronal loss of the subthalamic nucleus is a late feature in the CBD 
disease process, which is likely related to the downstream pathological involvement from the 
striatum, pars externa of the globus pallidus and substantia nigra within the basal ganglia 
circuit. 
 
In preclinical Cases 1 and 2, very mild tau lesions were observed in the hippocampal 
formation. There were more severe neuronal lesions in preclinical Case 3 but they may be 
attributable to coexisting argyrophilic grain disease pathology. In the fimbria, only very mild 
thread pathology was observed in Cases 1 and 2 but this was of moderate degree in Case 3. 
These findings suggest that tau pathology is minimal in the hippocampal formation in very 
early disease stage. It is likely that as the disease progresses, the hippocampus and fimbria, 
which is the white matter outflow of the hippocampus forming the fornix, become gradually 
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affected by tau pathology. Similar findings were observed in the amygdala, of which the 
regional tau load was very mild in Cases 1 and 2 (regional tau load: Case 1 = 0.51, Case 2 = 
0.48) and was much greater in Case 3 where argyrophilic grains were also present (regional 
tau load = 24.97)(Supplementary Fig. 1). Based on the findings in Cases 1 and 2, tau 
pathology in the amygdala is probably mild in very early disease stages in the absence of 
secondary pathology. Mild tau pathology in the amygdala was also observed in an incidental 
case (Case 1) recently reported by Nishida et al (Nishida et al., 2015).  
 
Only four preclinical CBD cases have been reported in the literature, two of which are 
included in this series (Cases 1(Ling et al., 2010) and 3(Milenkovic and Kovacs, 2013)). 
Recently, two preclinical (or early symptomatic cases) along with one clinically symptomatic 
end-stage CBD-bvFTD case were identified from 887 brains in a forensic autopsy series in 
Toyama, Japan, over a 6-year period, giving a pathological  incidence rate of 0.34%(Nishida 
et al., 2015). Case 1 of the Japanese report was a 65-year-old man who had died of smoke 
inhalation at the scene of a house fire. Case 2 was a 77-year-old woman diagnosed with 
dementia one month prior to death with a mini-mental state examination score of 21 out of 30 
points but did not experience any speech or motor impairments. She died of accidental 
drowning. Both cases had subtle clinical features consistent with early cognitive impairment. 
Histological examination of both cases revealed widespread tau pathology including 
neurofibrillary tangles, pretangles, astrocytic plaques in the fontal, parietal and temporal 
cortices, limbic, basal ganglia and brainstem structures. Ballooned neurons were observed in 
the frontal, temporal and limbic cortices. There was moderate neuronal loss in the substantia 
nigra in both cases. Numerous argyrophilic grains were found in the amygdala in Case 2 
(Stage II)(Saito et al., 2004; Nishida et al., 2015). The authors concluded that milder overall 
tau burden, sparse tau pathology in the superficial cortical layers, and the lack of volume loss 
or gliosis in the cortices, subcortical white matter and the corpus callosum as shown in their 
two cases were likely to be early histological features of CBD. In addition to these 
characteristics, our preclinical cases also exhibited much milder thread pathology which was 
restricted to the anterior frontal white matter and absent in other subcortical white matter, 
absent or rare ballooned neurons and preserved substantia nigra, suggesting our cases may 
represent an even earlier stage of CBD pathology when compared to the two cases described 
by Nishida et al.  
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While the preclinical cases in the present series represent very early (Cases 1 and 2) and early 
(Case 3) CBD pathology, the Japanese cases (Cases 1 and 2)(Nishida et al., 2015) most likely 
illustrate a continuum of early symptomatic CBD pathology. A pathological threshold that 
coincides with clinical disease onset is probably marked by an overall increase in tau burden 
especially in strategic brain regions accompanied by cortical spongiosis, nerve cell loss and 
the appearance of ballooned neurons as well as early nigral neuronal loss (Fig. 7). Future 
post-mortem studies of symptomatic patients with CBD who have died of other causes prior 
to reaching end-stage disease, will be of great value to demonstrate intermediate pathology 
prior to reaching a fully advanced disease stage.  
 
Argyrophilic grains can be observed in over 40% of end-stage CBD cases(Togo et al., 2002). 
The findings of argyrophilic grains in one of our preclinical cases (Case 3, Vienna) and in 
another early CBD case (Case 2) in the Japanese series suggest that argyrophilic grains may 
be a concomitant pathological feature that occurs early in the CBD pathological process. It is 
possible that these two distinct 4-repeat tauopathies, CBD and argyrophilic grain disease, 
share common characteristics which are relevant for the pathogenesis of both diseases. 
Moreover, the occasional ballooned neurons observed in limbic structures in our Case 3 are 
most likely driven by the coexisting argyrophilic grain disease rather than by the CBD 
pathological process(Saito et al., 2004). 
 
Preclinical cases of Alzheimer’s disease and Lewy body disease are common and their 
prevalence is much greater than the prevalence of their symptomatic counterparts(Bouras et 
al., 1994; Beach et al., 2009; Adler et al., 2010). On the other hand, preclinical cases of other 
neurodegenerative conditions are very rare, only six preclinical PSP(Oshima et al., 2004; 
Evidente et al., 2011) and two preclinical multiple system atrophy cases(Parkkinen et al., 
2007; Fujishiro et al., 2008) have been described in the literature. Evidente et al reported five 
preclinical PSP cases with frequent pathognomonic tufted astrocytes in the characteristic 
brain regions(Evidente et al., 2011). An association between H1 haplotype and 4-repeat 
tauopathies, including PSP and CBD, was previously reported and H1/H1 haplotype was 
identified in our preclinical Cases 1 and 3(Houlden et al., 2001).  
 
Our Case 1 died at the age of 63, but, notably, Case 2 in the present series died at age 89 and 
our Case 3 and Case 2 of the Japanese series also died at a relatively old age of 76 and 77, 
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respectively. Assuming that all five preclinical cases reported in the present and Japanese 
series had lived longer and that all cases soon went on to develop clinical symptoms, their 
estimated age at symptom onset (mean = 74) would have been significantly higher than that 
of the six end-stage CBD cases used as controls in the present study (mean = 64.2, P = 0.07, 
borderline significance) and that of our large end-stage CBD cohort (N = 109; mean = 64.6 
years, P = 0.01). In view of the fact that three of the five available preclinical cases were 
significantly older, there remains a possibility that some of these cases may represent a 
heterogeneous subgroup distinct from the typical CBD cases and our findings should be 
interpreted with cautions. Future studies are required to explore whether some of these older 
preclinical cases represent a more ‘benign’ subgroup due to the presence of distinct protective 
factors (such as H2 allele in our Case 2) or cognitive reserve (Case 2 also had a demanding 
professional occupation). This notion would be supported by existing findings in other 
neurodegenerative diseases such as Parkinson’s disease and PSP, of which phenotypic 
subgroups are segregated by age and disease duration (Williams et al., 2005; Halliday et al., 
2008). 
The study of preclinical CBD cases provides valuable insights into the early regions and 
lesion type affected by the CBD pathological process. These findings may serve as a basis for 
in vivo tau-imaging studies in patients with early symptoms to predict underlying CBD 
pathology, as well as the development of other biomarkers and disease-modifying treatments 
targeting early disease. Although the rarity of these preclinical cases coming to post-mortem 
makes further clarification of the true nature of these preclinical cases unlikely unless clinico-
pathological studies with a very large sample size are conducted, the widespread neuronal 
and glial tau lesions found in a typical anatomical distribution as observed in end-stage CBD 
and the presence of pathognomonic astrocytic plaques support our view that these cases 
represent early CBD and would have eventually evolved to symptomatic CBD.  
 
In summary, the earliest pathological features of CBD deduced from these three preclinical 
cases are: 1. Overall less tau burden, 2. astrocytic plaques are an early lesion type most 
prominent in the prefrontal cortex and striatum, 3. Relatively higher tau load in the anterior 
frontal cortex, striatum and subthalamic nucleus, suggesting striatal afferent connection to the 
dorsolateral prefrontal cortex and the basal ganglia circuitry may be the earliest neural 
network connections affected by CBD-tau(Ahmed et al., 2016), 4. Preserved substantia nigra, 
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and 5. Either absent or minimal cortical neuronal loss, superficial spongiosis and ballooned 
neurons. 
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Figure legends 
Fig. 1: 
Ballooned neurons (a & b; end-stage CBD Case 6) and astrocytic plaques (c-f; 
preclinical CBD Case 1).  
Ballooned neuron is absent in Cases 1 and 2. Occasional ballooned neurons observed in the 
cingulate cortex in Case 3 are probably associated with the coexisting argyrophilic grain 
disease rather than CBD pathology. Astrocytic plaque is a prominent histological finding in 
preclinical CBD cases, especially in the anterior frontal cortex (c-f) and caudate, and is 
immunoreactive for AT8 (c), AT100 (e) and 4-repeat tau (f), but not 3-repeat tau, and is 
Gallyas-positive (d). 1 cm scale bar = 10 µm. 
 
Fig. 2: 
Mean regional tau load (Log10) of preclinical CBD and end-stage CBD groups in 20 
selected brain regions.  
Error bars represent one standard error of the mean (SEM). ****P value < 0.001, ***P value: 
0.001-0.005, **P value: 0.005-0.01, *P value: 0.01-0.05, #P value: 0.05-0.01 (borderline 
statistical significance), Student’s t-test; AFG: anterior frontal grey matter, AFW: anterior 
frontal white matter, PFG: posterior frontal grey matter, PFW: posterior frontal white matter, 
PRG: parietal grey matter, PR: parietal white matter, TMG: temporal grey matter, TMW: 
temporal white matter, HIP: hippocampus, AMG: amygdala, CAU: caudate, PUT: putamen, 
GLP: globus pallidus, STN: subthalamic nucleus, MTC: midbrain tectum, MTG: midbrain 
tegmentum, PTG: pontine tegmentum, PBS: pontine base, CDN: cerebellar dentate nucleus 
and CWM: cerebellar white matter. 
 
Fig. 3: 
Tau immunohistochemistry (AT8) sections of the three preclinical CBD cases (Cases 1-
3) and one end-stage CBD-CBS case (Case 4). 1 cm scale bar = 38.5 µm. 
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Fig. 4: 
Anterior and posterior frontal cortex of two preclinical CBD (Cases 1 and 3) and one 
end-stage CBD-CBS case (Case 6).  
The characteristic features of cortical neuronal loss and superficial spongiosis are observed in 
the end-stage CBD case (c & i) but not in the preclinical CBD cases (a, b & g, h). In the 
preclinical CBD cases, tau immunohistochemistry (AT8) demonstrates tau lesions, mainly in 
the form of astrocytic plaques, are more abundant in the anterior frontal cortex (d & e) than in 
the posterior frontal cortex (j & k). This anterior-posterior gradient is most apparent in Case 1 
(d & j), which has a relatively less total tau load and is thought to represent an earlier stage of 
CBD pathology than Case 3. On the contrary, in the end-stage CBD case, neurofibrillary 
tangles and neuropil threads are much more frequent than astrocytic plaques and the tau 
distribution is more severe in the posterior frontal cortex (l) than in the anterior frontal cortex 
(f). H&E: a-c, g-i; tau immunohistochemistry (AT8): d-f, j-l; 1 cm scale bar = 100µm. 
 
Fig. 5: 
Distribution and severity of tau-immunoreactive cellular lesions in preclinical and end-
stage CBD groups.  
A summary of the tau pathology in three preclinical CBD and six end-stage CBD (3 CBD-
CBS and 3 CBD-RS) cases using mean lesion count for neuronal lesions, astrocytic plaques 
and coiled bodies and a 4-tier semi-quantitative scores for neuropil thread (0 = none, 1 = 
mild, 2 = moderate, 3 = severe) assessed at x20 objective in five random fields (except for 
substantia nigra, subthalamic and dentate nuclei where three random fields were used due to 
small regional areas).  The severity of tau pathology is colour-coded with a heat map, with 
more severely affected areas showing hotter colours (red, orange and yellow) and less 
affected areas represented by cooler colours (green and blue). 
 
Fig. 6: 
H&E sections of the substantia nigra. 
The substantia nigra of the three preclinical CBD Cases 1-3 and an 82-year-old healthy 
control are relatively preserved with a good population of pigmented neurons. Severe loss of 
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pigmented neurons, gliosis and scaring are observed in the substantia nigra of the end-stage 
CBD-RS Case 8. 1 cm scale bar = 100 µm. 
 
Fig. 7: 
Characteristic features of the pathological progression of CBD. 
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Table 1: Characteristics and secondary pathologies of preclinical CBD (Cases 1-3) and end-stage CBD (Cases 4-9) cases. 
Case No. Gender Clinical 
diagnosis 
Age at 
death 
(years) 
Disease 
duration 
from 
symptom 
onset 
(years) 
Clinically 
more 
affected 
side 
Whole 
brain 
weight  
Hemisphere 
examined* 
NIA-AA score 
(Level of AD 
neuropathological 
change)(Hyman et 
al., 2012)  
TDP-43 
proteinopathy 
Argyrophilic 
grains(Saito 
et al., 2004)  
C9Orf72 
inclusions*
* 
α-
synuclein 
pathology 
Vascular 
pathology 
CAA 
Case 1 
(Preclinical, 
QSBB) 
Male Tourette’s 
Syndrome 
63 NA NA 1441g Left A0, B1, C0 (Not) - - - - - - 
Case 2  
(Preclinical, 
New York) 
Male US Aging 
Project 
89 NA NA 1315g Right A1, B0, C0 (Low) - - - - - - 
Case 3  
(Preclinical, 
Vienna) 
Female Kidney 
Transplant 
76 NA NA 1120g Left A0, B1, C0 (Not) - Yes  - - - - 
Case 4  
(End-stage 
CBD-CBS) 
Male CBS 78 8 Right  1216g Right  A1, B1, C1 (Low) - - - - - - 
Case 5  
(End-stage 
CBD-CBS) 
Male CBS 72 5 Left 1378g Left A0, B2, C0 (Not) - - - - Mild SVD - 
Case 6  
(End-stage 
CBD-CBS) 
Male CBS 73 7 Left 1154g Left A0, B1, C0 (Not) - - - - Mild SVD - 
Case 7  
(End-stage 
CBD-RS) 
Female RS 68 5 NA 1034g Left A1, B1, C1 (Low) Limbic Yes - - - - 
Case 8  
(End-stage 
CBD-RS) 
Male RS 64 4 NA 1210g Left A1, B1, C1 (Low) Limbic Yes - - Mild SVD - 
Case 9  
(End-stage 
CBD-RS) 
Male RS 66 4 NA 1200g Right A1, B1, C1 (Low) Limbic Yes - - - Mild 
 
AD: Alzheimer’s disease, CAA: cerebral amyloid angiopathy, CBD: corticobasal degeneration, CBS: corticobasal syndrome, NA: not applicable, NK: not 
known, QSBB: Queen Square Brain Bank for Neurological Disorders, London, UK, RS: Richardson syndrome, US: United States, SVD: small vessel disease; 
*hemisphere examined was randomly selected, **screening for inclusions using p62 immunohistochemistry in hippocampus and cerebellum, -: negative/absent. 
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Ballooned neurons (a & b; end-stage CBD Case 6) and astrocytic plaques (c-f; preclinical CBD Case 1).  
Ballooned neuron is absent in Cases 1 and 2. Occasional ballooned neurons observed in the cingulate cortex 
in Case 3 are probably associated with the coexisting argyrophilic grain disease rather than CBD pathology. 
Astrocytic plaque is a prominent histological finding in preclinical CBD cases, especially in the anterior frontal 
cortex (c-f) and caudate, and is immunoreactive for AT8 (c), AT100 (e) and 4-repeat tau (f), but not 3-
repeat tau, and is Gallyas-positive (d). 1 cm scale bar = 10 µm.  
 
Fig. 1  
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Mean regional tau load (Log10) of preclinical CBD and end-stage CBD groups in 20 selected brain regions.  
Error bars represent one standard error of the mean (SEM). ****P value < 0.001, ***P value: 0.001-0.005, 
**P value: 0.005-0.01, *P value: 0.01-0.05, #P value: 0.05-0.01 (borderline statistical significance), 
Student’s t-test; AFG: anterior frontal grey matter, AFW: anterior frontal white matter, PFG: posterior 
frontal grey matter, PFW: posterior frontal white matter, PRG: parietal grey matter, PR: parietal white 
matter, TMG: temporal grey matter, TMW: temporal white matter, HIP: hippocampus, AMG: amygdala, 
CAU: caudate, PUT: putamen, GLP: globus pallidus, STN: subthalamic nucleus, MTC: midbrain tectum, MTG: 
midbrain tegmentum, PTG: pontine tegmentum, PBS: pontine base, CDN: cerebellar dentate nucleus and 
CWM: cerebellar white matter.  
 
Fig. 2  
370x250mm (96 x 96 DPI)  
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Tau immunohistochemistry (AT8) sections of the three preclinical CBD cases (Cases 1-3) and one end-stage 
CBD-CBS case (Case 4). 1 cm scale bar = 38.5 µm.  
Fig. 3  
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Anterior and posterior frontal cortex of two preclinical CBD (Cases 1 and 3) and one end-stage CBD-CBS 
 case (Case 6). The characteristic features of cortical neuronal loss and superficial spongiosis are 
observed in the end-stage CBD case (c & i) but not in the preclinical CBD cases (a, b & g, h). In the 
preclinical CBD cases, tau immunohistochemistry (AT8) demonstrates tau lesions, mainly in the form of 
astrocytic plaques, are more abundant in the anterior frontal cortex (d & e) than in the posterior frontal 
cortex (j & k). This anterior-posterior gradient is most apparent in Case 1 (d & j), which has a relatively less 
total tau load and is thought to represent an earlier stage of CBD pathology than Case 3. On the contrary, in 
the end-stage CBD case, neurofibrillary tangles and neuropil threads are much more frequent than 
astrocytic plaques and the tau distribution is more severe in the posterior frontal cortex (l) than in the 
anterior frontal cortex (f). H&E: a-c, g-i; tau immunohistochemistry (AT8): d-f, j-l; 1 cm scale bar = 
 100µm.   
Fig. 4  
199x178mm (300 x 300 DPI)  
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Distribution and severity of tau-immunoreactive cellular lesions in preclinical and end-stage CBD groups. 
  A summary of the tau pathology in 3 preclinical CBD and 6 end-stage CBD (3 CBD-CBS and 3 CBD-RS) 
cases using mean lesion count for neuronal lesions, astrocytic plaques and coiled bodies and a 4-tier semi-
quantitative scores for neuropil thread (0 = none, 1 = mild, 2 = moderate, 3 = severe) assessed at x20 
objective in 5 random fields (except for substantia nigra, subthalamic and dentate nuclei where 3 random 
fields were used due to small regional areas).  The severity of tau pathology is colour-coded with a heat 
map, with more severely affected areas showing hotter colours (red, orange and yellow) and less affected 
areas represented by  cooler colours (green and blue).   
Fig. 5  
550x550mm (96 x 96 DPI)  
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 H&E sections of the substanti nigra. The substantia nigra of the three preclinical CBD Cases 1-3 and an 
82-year-old healthy control are relatively preserved with a good population of pigmented neurons. Severe 
loss of pigmented neurons, gliosis and scaring are observed in the substantia nigra of the end-stage CBD-RS 
 Case 8. 1 cm scale bar = 100 µm.   
Fig. 6  
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Characteristic features of the pathological progression of CBD.  
Fig. 7  
338x190mm (96 x 96 DPI)  
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SUPPLEMENTARY MATERIALS 
 
Supplementary Fig. 1: 
Regional tau load determined by measuring all tau immunoreactive lesions by image analysis 
in each preclinical case (Cases 1 to 3; data provided in brackets). Only selected brain regions 
are illustrated. In Case 3, tissue sections of the posterior frontal region and subthalamic 
nucleus were not available for analysis. GM: grey matter, WM: white matter. 
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Supplementary Fig. 2: 
Mean total, cortical and basal ganglia tau load of preclinical CBD and end-stage CBD 
groups. 
Error bars represent one standard error of the mean (SEM). ***P value: 0.001-0.005, *P 
value: 0.01-0.05, #P value: 0.05-0.01 (borderline statistical significance), Student’s t-test; 
BG: basal ganglia. 
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Supplementary Fig. 3: 
Tau pathology in the cortical regions of the preclinical and end-stage CBD groups.  
Mean lesion count for neuronal lesions, astrocytic plaques and coiled bodies and a 4-tier 
semi-quantitative grading scores for neuropil thread were assessed at x20 objective in 5 
random fields in the anterior and posterior frontal, parietal and temporal grey matter and 
white matter. Supplementary Fig 3 illustrates the mean count of neuronal lesions and 
astrocytic plaques in the two groups. Error bars represent one standard error of the mean 
(SEM). 
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Supplementary Fig. 4: 
Correlations between lesion types and tau load in the cortical regions. In preclinical CBD 
cases, significant correlation was found between neuronal lesions and regional tau load 
(Pearson correlation coefficient = 0.95). In end-stage CBD, significant correlation was found 
between thread pathology and regional tau load (Pearson correlation coefficient = 0.86). 
Regions included in the analysis were anterior and posterior frontal, parietal and temporal 
grey matter and white matter.  
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Supplementary Fig. 5: 
Tau-immunoreactive neuronal and thread lesions in the hippocampal subregions of 
preclinical and end-stage CBD cases. A 4-tier semi-quantitative grading scheme was used: 
0 = none, 1 = mild, 2 = moderate, 3 = severe. AD: Alzheimer’s disease, EC: entorhinal 
cortex, GCL: granular cell layer, NFT: neurofibrillary tangle, PreT: pretangle. NIA-AA ABC 
score (Hyman et al., 2012), argyrophilic grains (Saito et al., 2004). 
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